News

As per the terms of the agreement Pepscan is expected to receive an undisclosed cash payment as well as a minority interest in Immunovo. Wim Mol, CEO of

KRN5500 is a non-opioid analgesic agent, a semi-synthetic derivative of spicamycin: (6-[4-Deoxy-4-[(2E,4E)-tetradecadienoylglycyl]amino-L-glycero-B-L-manno-heptopyranosyl]amino-9H-purine). As per the terms of the collaboration, NCI is expected to fund the studies and Dara

Abbott said that Kaletra once-daily dosing is already indicated for adult patients new to antiretroviral treatment. This gives treatment-experienced patients who have HIV that responds to Kaletra another

Suven said that the patents are valid until 2024 and 2025 respectively. The granted claims of the patents include the class of selective 5-HT compounds discovered by the

Reportedly, Piramal Healthcare is in talks with Sanofi Aventis and Glaxo Smithkline to sell its domestic formulation business which currently contributes 55% of revenues. The acquisition is expected

The agreements also settle all litigation between Synergetics and Alcon. As provided by the settlement and license agreement and supply agreement, Alcon is expected to pay Synergetics approximately

Flomax is used to treat the symptoms of an enlarged prostate. Flomax doesn’t shrink the prostate. Instead, it relaxes the muscle around it, freeing the flow of urine

The second Phase I/II trial was a randomised, single-blind, placebo-controlled, escalating double-dose safety study conducted at the Sourasky Medical Center in Tel Aviv, Israel, in which a total

Discovered by Takeda, Azilsartan medoxomil is designed to lower blood pressure by blocking the action of a vasopressor hormone, angiotensin II. Takeda Pharmaceutical said that the NDA submission